Global Human Vaccines Administered Orally Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Publisher Name :
Date: 23-Nov-2022
No. of pages: 124
Inquire Before Buying

Oral vaccines are safe and easy to administer and convenient for all ages. They have been successfully developed to protect from many infectious diseases acquired through oral transmission. Oral delivery of vaccines represents the most attractive mode of administration over other routes of delivery due to the fact that the oral vaccination is noninvasive, safe and simple to execute, showing good patient compliance and clinical practicality.

Report Overview

Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.

The USA market for Human Vaccines Administered Orally is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

The China market for Human Vaccines Administered Orally is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

The Europe market for Human Vaccines Administered Orally is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

The global key manufacturers of Human Vaccines Administered Orally include Merck, GSK, Sanofi, Lanzhou Institute, Serum Institute, Valneva, Shanghai United Cell, Bibcol and PaxVax, etc. In 2021, the global top five players had a share approximately % in terms of revenue.

Report Scope

This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers' production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Human Vaccines Administered Orally manufacturers, distributors, end users, industry associations, governments' industry bureaus, industry publications, industry experts, third party database, and our in-house databases.

This report also includes a discussion of the major players across each regional Human Vaccines Administered Orally market. Further, it explains the major drivers and regional dynamics of the global Human Vaccines Administered Orally market and current trends within the industry.

Key Companies Covered

In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:

- Merck

- GSK

- Sanofi

- Lanzhou Institute

- Serum Institute

- Valneva

- Shanghai United Cell

- Bibcol

- PaxVax

- Vabiotech

- Tiantan Biological

- EuBiologics

- Panacea Biotec Ltd

- Bio-Med

- Halfkin Bio-Pharmaceuticals

Market Segments

This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.

Human Vaccines Administered Orally Segment by Type

- Rotavirus Vaccine

- Cholera Vaccine

- Oral Polio Vaccine

Human Vaccines Administered Orally Segment by Application

- Public

- Private

Key Regions & Countries

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.

- North America

- - United States

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Australia

- - China Taiwan

- - Indonesia

- - Thailand

- - Malaysia

- Latin America

- - Mexico

- - Brazil

- - Argentina

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Human Vaccines Administered Orally market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Report Includes:

This report presents an overview of global market for Human Vaccines Administered Orally, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028.

This report researches the key producers of Human Vaccines Administered Orally, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Human Vaccines Administered Orally, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Human Vaccines Administered Orally sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Human Vaccines Administered Orally market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Human Vaccines Administered Orally sales, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Merck, GSK, Sanofi, Lanzhou Institute, Serum Institute, Valneva, Shanghai United Cell, Bibcol and PaxVax, etc.

Global Human Vaccines Administered Orally Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Table of Contents
1 Report Overview
1.1 Research Scope
1.2 Market Segment by Type
1.2.1 Global Human Vaccines Administered Orally Market Size Growth Rate by Type (2017 VS 2021 VS 2028)
1.2.2 Rotavirus Vaccine
1.2.3 Cholera Vaccine
1.2.4 Oral Polio Vaccine
1.3 Market Segment by Application
1.3.1 Global Human Vaccines Administered Orally Market Share by Application (2017 VS 2021 VS 2028)
1.3.2 Public
1.3.3 Private
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Human Vaccines Administered Orally Market Size (2017-2028)
2.1.1 Global Human Vaccines Administered Orally Revenue (2017-2028)
2.1.2 Global Human Vaccines Administered Orally Sales (2017-2028)
2.2 Global Human Vaccines Administered Orally Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028
2.2.1 Global Human Vaccines Administered Orally Sales by Regions (2017-2022)
2.2.2 Global Human Vaccines Administered Orally Revenue by Regions (2017-2022)
2.3 Global Human Vaccines Administered Orally Market Size Forecast by Region
2.3.1 Global Human Vaccines Administered Orally Sales Forecast by Region (2023-2028)
2.3.2 Global Human Vaccines Administered Orally Revenue Forecast by Region (2023-2028)
2.4 Global Top Human Vaccines Administered Orally Regions (Countries) Ranking by Market Size
2.5 Human Vaccines Administered Orally Market Dynamics
2.5.1 Human Vaccines Administered Orally Market Trends
2.5.2 Human Vaccines Administered Orally Market Drivers
2.5.3 Human Vaccines Administered Orally Market Challenges
2.5.4 Human Vaccines Administered Orally Market Restraints
3 Competitive Landscape by Manufacturers
3.1 Global Top Human Vaccines Administered Orally Manufacturers by Sales (2017-2022)
3.1.1 Global Human Vaccines Administered Orally Sales by Manufacturers (2017-2022)
3.1.2 Global Human Vaccines Administered Orally Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global 5 and 10 Largest Manufacturers by Human Vaccines Administered Orally Sales in 2021
3.2 Global Top Manufacturers Human Vaccines Administered Orally by Revenue
3.2.1 Global Human Vaccines Administered Orally Revenue by Manufacturers (2017-2022)
3.2.2 Top Human Vaccines Administered Orally Manufacturers Covered: Ranking by Revenue
3.2.3 Global Human Vaccines Administered Orally Revenue Share by Manufacturers (2017-2022)
3.2.4 Global Human Vaccines Administered Orally Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Human Vaccines Administered Orally as of 2021)
3.4 Global Human Vaccines Administered Orally Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Human Vaccines Administered Orally Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Human Vaccines Administered Orally Market
3.7 Key Manufacturers Human Vaccines Administered Orally Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Human Vaccines Administered Orally Market Size by Type
4.1 Global Human Vaccines Administered Orally Historic Market Review by Type (2017-2022)
4.1.1 Global Human Vaccines Administered Orally Sales Market Share by Type (2017-2022)
4.1.2 Global Human Vaccines Administered Orally Revenue Market Share by Type (2017-2022)
4.1.3 Human Vaccines Administered Orally Price by Type (2017-2022)
4.2 Global Human Vaccines Administered Orally Market Estimates and Forecasts by Type (2023-2028)
4.2.1 Global Human Vaccines Administered Orally Sales Forecast by Type (2023-2028)
4.2.2 Global Human Vaccines Administered Orally Revenue Forecast by Type (2023-2028)
4.2.3 Human Vaccines Administered Orally Price Forecast by Type (2023-2028)
5 Global Human Vaccines Administered Orally Market Size by Application
5.1 Global Human Vaccines Administered Orally Historic Market Review by Application (2017-2022)
5.1.1 Global Human Vaccines Administered Orally Sales Market Share by Application (2017-2022)
5.1.2 Global Human Vaccines Administered Orally Revenue Market Share by Application (2017-2022)
5.1.3 Human Vaccines Administered Orally Price by Application (2017-2022)
5.2 Global Human Vaccines Administered Orally Market Estimates and Forecasts by Application (2023-2028)
5.2.1 Global Human Vaccines Administered Orally Sales Forecast by Application (2023-2028)
5.2.2 Global Human Vaccines Administered Orally Revenue Forecast by Application (2023-2028)
5.2.3 Human Vaccines Administered Orally Price Forecast by Application (2023-2028)
6 North America
6.1 North America Human Vaccines Administered Orally Sales Breakdown by Company
6.1.1 North America Human Vaccines Administered Orally Sales by Company (2017-2022)
6.1.2 North America Human Vaccines Administered Orally Revenue by Company (2017-2022)
6.2 North America Human Vaccines Administered Orally Market Size by Type
6.2.1 North America Human Vaccines Administered Orally Sales by Type (2017-2028)
6.2.2 North America Human Vaccines Administered Orally Revenue by Type (2017-2028)
6.3 North America Human Vaccines Administered Orally Market Size by Application
6.3.1 North America Human Vaccines Administered Orally Sales by Application (2017-2028)
6.3.2 North America Human Vaccines Administered Orally Revenue by Application (2017-2028)
6.4 North America Human Vaccines Administered Orally Market Size by Country
6.4.1 North America Human Vaccines Administered Orally Sales by Country (2017-2028)
6.4.2 North America Human Vaccines Administered Orally Revenue by Country (2017-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Human Vaccines Administered Orally Sales Breakdown by Company
7.1.1 Europe Human Vaccines Administered Orally Sales by Company (2017-2022)
7.1.2 Europe Human Vaccines Administered Orally Revenue by Company (2017-2022)
7.2 Europe Human Vaccines Administered Orally Market Size by Type
7.2.1 Europe Human Vaccines Administered Orally Sales by Type (2017-2028)
7.2.2 Europe Human Vaccines Administered Orally Revenue by Type (2017-2028)
7.3 Europe Human Vaccines Administered Orally Market Size by Application
7.3.1 Europe Human Vaccines Administered Orally Sales by Application (2017-2028)
7.3.2 Europe Human Vaccines Administered Orally Revenue by Application (2017-2028)
7.4 Europe Human Vaccines Administered Orally Market Size by Country
7.4.1 Europe Human Vaccines Administered Orally Sales by Country (2017-2028)
7.4.2 Europe Human Vaccines Administered Orally Revenue by Country (2017-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Human Vaccines Administered Orally Sales Breakdown by Company
8.1.1 Asia Pacific Human Vaccines Administered Orally Sales by Company (2017-2022)
8.1.2 Asia Pacific Human Vaccines Administered Orally Revenue by Company (2017-2022)
8.2 Asia Pacific Human Vaccines Administered Orally Market Size by Type
8.2.1 Asia Pacific Human Vaccines Administered Orally Sales by Type (2017-2028)
8.2.2 Asia Pacific Human Vaccines Administered Orally Revenue by Type (2017-2028)
8.3 Asia Pacific Human Vaccines Administered Orally Market Size by Application
8.3.1 Asia Pacific Human Vaccines Administered Orally Sales by Application (2017-2028)
8.3.2 Asia Pacific Human Vaccines Administered Orally Revenue by Application (2017-2028)
8.4 Asia Pacific Human Vaccines Administered Orally Market Size by Region
8.4.1 Asia Pacific Human Vaccines Administered Orally Sales by Region
8.4.2 Asia Pacific Human Vaccines Administered Orally Revenue by Region
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 China Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
9 Latin America
9.1 Latin America Human Vaccines Administered Orally Sales Breakdown by Company
9.1.1 Latin America Human Vaccines Administered Orally Sales by Company (2017-2022)
9.1.2 Latin America Human Vaccines Administered Orally Revenue by Company (2017-2022)
9.2 Latin America Human Vaccines Administered Orally Market Size by Type
9.2.1 Latin America Human Vaccines Administered Orally Sales by Type (2017-2028)
9.2.2 Latin America Human Vaccines Administered Orally Revenue by Type (2017-2028)
9.3 Latin America Human Vaccines Administered Orally Market Size by Application
9.3.1 Latin America Human Vaccines Administered Orally Sales by Application (2017-2028)
9.3.2 Latin America Human Vaccines Administered Orally Revenue by Application (2017-2028)
9.4 Latin America Human Vaccines Administered Orally Market Size by Country
9.4.1 Latin America Human Vaccines Administered Orally Sales by Country (2017-2028)
9.4.2 Latin America Human Vaccines Administered Orally Revenue by Country (2017-2028)
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Human Vaccines Administered Orally Sales Breakdown by Company
10.1.1 Middle East and Africa Human Vaccines Administered Orally Sales by Company (2017-2022)
10.1.2 Middle East and Africa Human Vaccines Administered Orally Revenue by Company (2017-2022)
10.2 Middle East and Africa Human Vaccines Administered Orally Market Size by Type
10.2.1 Middle East and Africa Human Vaccines Administered Orally Sales by Type (2017-2028)
10.2.2 Middle East and Africa Human Vaccines Administered Orally Revenue by Type (2017-2028)
10.3 Middle East and Africa Human Vaccines Administered Orally Market Size by Application
10.3.1 Middle East and Africa Human Vaccines Administered Orally Sales by Application (2017-2028)
10.3.2 Middle East and Africa Human Vaccines Administered Orally Revenue by Application (2017-2028)
10.4 Middle East and Africa Human Vaccines Administered Orally Market Size by Country
10.4.1 Middle East and Africa Human Vaccines Administered Orally Sales by Country (2017-2028)
10.4.2 Middle East and Africa Human Vaccines Administered Orally Revenue by Country (2017-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Company Profiles
11.1 Merck
11.1.1 Merck Corporation Information
11.1.2 Merck Overview
11.1.3 Merck Human Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.1.4 Merck Human Vaccines Administered Orally Products and Services
11.1.5 Merck Human Vaccines Administered Orally SWOT Analysis
11.1.6 Merck Recent Developments
11.2 GSK
11.2.1 GSK Corporation Information
11.2.2 GSK Overview
11.2.3 GSK Human Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.2.4 GSK Human Vaccines Administered Orally Products and Services
11.2.5 GSK Human Vaccines Administered Orally SWOT Analysis
11.2.6 GSK Recent Developments
11.3 Sanofi
11.3.1 Sanofi Corporation Information
11.3.2 Sanofi Overview
11.3.3 Sanofi Human Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.3.4 Sanofi Human Vaccines Administered Orally Products and Services
11.3.5 Sanofi Human Vaccines Administered Orally SWOT Analysis
11.3.6 Sanofi Recent Developments
11.4 Lanzhou Institute
11.4.1 Lanzhou Institute Corporation Information
11.4.2 Lanzhou Institute Overview
11.4.3 Lanzhou Institute Human Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.4.4 Lanzhou Institute Human Vaccines Administered Orally Products and Services
11.4.5 Lanzhou Institute Human Vaccines Administered Orally SWOT Analysis
11.4.6 Lanzhou Institute Recent Developments
11.5 Serum Institute
11.5.1 Serum Institute Corporation Information
11.5.2 Serum Institute Overview
11.5.3 Serum Institute Human Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.5.4 Serum Institute Human Vaccines Administered Orally Products and Services
11.5.5 Serum Institute Human Vaccines Administered Orally SWOT Analysis
11.5.6 Serum Institute Recent Developments
11.6 Valneva
11.6.1 Valneva Corporation Information
11.6.2 Valneva Overview
11.6.3 Valneva Human Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.6.4 Valneva Human Vaccines Administered Orally Products and Services
11.6.5 Valneva Human Vaccines Administered Orally SWOT Analysis
11.6.6 Valneva Recent Developments
11.7 Shanghai United Cell
11.7.1 Shanghai United Cell Corporation Information
11.7.2 Shanghai United Cell Overview
11.7.3 Shanghai United Cell Human Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.7.4 Shanghai United Cell Human Vaccines Administered Orally Products and Services
11.7.5 Shanghai United Cell Human Vaccines Administered Orally SWOT Analysis
11.7.6 Shanghai United Cell Recent Developments
11.8 Bibcol
11.8.1 Bibcol Corporation Information
11.8.2 Bibcol Overview
11.8.3 Bibcol Human Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.8.4 Bibcol Human Vaccines Administered Orally Products and Services
11.8.5 Bibcol Human Vaccines Administered Orally SWOT Analysis
11.8.6 Bibcol Recent Developments
11.9 PaxVax
11.9.1 PaxVax Corporation Information
11.9.2 PaxVax Overview
11.9.3 PaxVax Human Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.9.4 PaxVax Human Vaccines Administered Orally Products and Services
11.9.5 PaxVax Human Vaccines Administered Orally SWOT Analysis
11.9.6 PaxVax Recent Developments
11.10 Vabiotech
11.10.1 Vabiotech Corporation Information
11.10.2 Vabiotech Overview
11.10.3 Vabiotech Human Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.10.4 Vabiotech Human Vaccines Administered Orally Products and Services
11.10.5 Vabiotech Human Vaccines Administered Orally SWOT Analysis
11.10.6 Vabiotech Recent Developments
11.11 Tiantan Biological
11.11.1 Tiantan Biological Corporation Information
11.11.2 Tiantan Biological Overview
11.11.3 Tiantan Biological Human Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.11.4 Tiantan Biological Human Vaccines Administered Orally Products and Services
11.11.5 Tiantan Biological Recent Developments
11.12 EuBiologics
11.12.1 EuBiologics Corporation Information
11.12.2 EuBiologics Overview
11.12.3 EuBiologics Human Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.12.4 EuBiologics Human Vaccines Administered Orally Products and Services
11.12.5 EuBiologics Recent Developments
11.13 Panacea Biotec Ltd
11.13.1 Panacea Biotec Ltd Corporation Information
11.13.2 Panacea Biotec Ltd Overview
11.13.3 Panacea Biotec Ltd Human Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.13.4 Panacea Biotec Ltd Human Vaccines Administered Orally Products and Services
11.13.5 Panacea Biotec Ltd Recent Developments
11.14 Bio-Med
11.14.1 Bio-Med Corporation Information
11.14.2 Bio-Med Overview
11.14.3 Bio-Med Human Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.14.4 Bio-Med Human Vaccines Administered Orally Products and Services
11.14.5 Bio-Med Recent Developments
11.15 Halfkin Bio-Pharmaceuticals
11.15.1 Halfkin Bio-Pharmaceuticals Corporation Information
11.15.2 Halfkin Bio-Pharmaceuticals Overview
11.15.3 Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.15.4 Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Products and Services
11.15.5 Halfkin Bio-Pharmaceuticals Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Human Vaccines Administered Orally Value Chain Analysis
12.2 Human Vaccines Administered Orally Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Human Vaccines Administered Orally Production Mode & Process
12.4 Human Vaccines Administered Orally Sales and Marketing
12.4.1 Human Vaccines Administered Orally Sales Channels
12.4.2 Human Vaccines Administered Orally Distributors
12.5 Human Vaccines Administered Orally Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
List of Tables
Table 1. Global Human Vaccines Administered Orally Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Rotavirus Vaccine
Table 3. Major Manufacturers of Cholera Vaccine
Table 4. Major Manufacturers of Oral Polio Vaccine
Table 5. Global Human Vaccines Administered Orally Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Human Vaccines Administered Orally Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028
Table 7. Global Human Vaccines Administered Orally Sales by Region (2017-2022) & (K Units)
Table 8. Global Human Vaccines Administered Orally Sales Market Share by Region (2017-2022)
Table 9. Global Human Vaccines Administered Orally Revenue by Region (2017-2022) & (US$ Million)
Table 10. Global Human Vaccines Administered Orally Revenue Market Share by Region (2017-2022)
Table 11. Global Human Vaccines Administered Orally Sales Forecast by Region (2023-2028) & (K Units)
Table 12. Global Human Vaccines Administered Orally Sales Market Share Forecast by Region (2023-2028)
Table 13. Global Human Vaccines Administered Orally Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 14. Global Human Vaccines Administered Orally Revenue Market Share Forecast by Region (2023-2028)
Table 15. Top Human Vaccines Administered Orally Regions (Countries) Ranking by Market Size (US$ Million) in 2021
Table 16. Human Vaccines Administered Orally Market Trends
Table 17. Human Vaccines Administered Orally Market Drivers
Table 18. Human Vaccines Administered Orally Market Challenges
Table 19. Human Vaccines Administered Orally Market Restraints
Table 20. Global Human Vaccines Administered Orally Sales by Manufacturers (2017-2022) & (K Units)
Table 21. Global Human Vaccines Administered Orally Sales Share by Manufacturers (2017-2022)
Table 22. Global Human Vaccines Administered Orally Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 23. Ranking of Global Top Human Vaccines Administered Orally Manufacturers by Revenue (US$ Million) in 2021
Table 24. Human Vaccines Administered Orally Revenue Share by Manufacturers (2017-2022)
Table 25. Global Human Vaccines Administered Orally Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 26. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Human Vaccines Administered Orally as of 2021)
Table 27. Key Manufacturers Human Vaccines Administered Orally Average Selling Price (ASP) & (2017-2022) & (US$/Unit)
Table 28. Key Manufacturers Human Vaccines Administered Orally Plants/Factories Distribution
Table 29. Key Manufacturers Human Vaccines Administered Orally Area Served
Table 30. Date of Key Manufacturers Enter into Human Vaccines Administered Orally Market
Table 31. Key Manufacturers Human Vaccines Administered Orally Product Type
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Human Vaccines Administered Orally Sales (K Units) by Type (2017-2022)
Table 34. Global Human Vaccines Administered Orally Sales Share by Type (2017-2022)
Table 35. Global Human Vaccines Administered Orally Revenue (US$ Million) Market Share by Type (2017-2022)
Table 36. Global Human Vaccines Administered Orally Price (K Units) by Type (2017-2022)
Table 37. Global Human Vaccines Administered Orally Sales (K Units) by Type (2023-2028)
Table 38. Global Human Vaccines Administered Orally Sales Share by Type (2023-2028)
Table 39. Global Human Vaccines Administered Orally Revenue (US$ Million) Market Share by Type (2023-2028)
Table 40. Global Human Vaccines Administered Orally Revenue Share by Type (2023-2028)
Table 41. Global Human Vaccines Administered Orally Price (K Units) by Type (2023-2028)
Table 42. Global Human Vaccines Administered Orally Sales (K Units) by Application (2017-2022)
Table 43. Global Human Vaccines Administered Orally Sales Share by Application (2017-2022)
Table 44. Global Human Vaccines Administered Orally Revenue (US$ Million) Market Share by Application (2017-2022)
Table 45. Global Human Vaccines Administered Orally Price (K Units) by Application (2017-2022)
Table 46. Global Human Vaccines Administered Orally Sales (K Units) by Application (2023-2028)
Table 47. Global Human Vaccines Administered Orally Sales Share by Application (2023-2028)
Table 48. Global Human Vaccines Administered Orally Revenue (US$ Million) Market Share by Application (2023-2028)
Table 49. Global Human Vaccines Administered Orally Revenue Share by Application (2023-2028)
Table 50. Global Human Vaccines Administered Orally Price (K Units) by Application (2023-2028)
Table 51. North America Human Vaccines Administered Orally Sales by Company (2017-2022) & (K Units)
Table 52. North America Human Vaccines Administered Orally Sales Market Share by Company (2017-2022)
Table 53. North America Human Vaccines Administered Orally Revenue by Company (2017-2022) & (US$ Million)
Table 54. North America Human Vaccines Administered Orally Revenue Market Share by Company (2017-2022)
Table 55. North America Human Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
Table 56. North America Human Vaccines Administered Orally Sales by Type (2023-2028) & (K Units)
Table 57. North America Human Vaccines Administered Orally Revenue by Type (2017-2022) & (US$ Million)
Table 58. North America Human Vaccines Administered Orally Revenue by Type (2023-2028) & (US$ Million)
Table 59. North America Human Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
Table 60. North America Human Vaccines Administered Orally Sales by Application (2023-2028) & (K Units)
Table 61. North America Human Vaccines Administered Orally Revenue by Application (2017-2022) & (US$ Million)
Table 62. North America Human Vaccines Administered Orally Revenue by Application (2023-2028) & (US$ Million)
Table 63. North America Human Vaccines Administered Orally Sales by Country (2017-2022) & (K Units)
Table 64. North America Human Vaccines Administered Orally Sales by Country (2023-2028) & (K Units)
Table 65. North America Human Vaccines Administered Orally Revenue by Country (2017-2022) & (US$ Million)
Table 66. North America Human Vaccines Administered Orally Revenue by Country (2023-2028) & (US$ Million)
Table 67. Europe Human Vaccines Administered Orally Sales by Company (2017-2022) & (K Units)
Table 68. Europe Human Vaccines Administered Orally Sales Market Share by Company (2017-2022)
Table 69. Europe Human Vaccines Administered Orally Revenue by Company (2017-2022) & (US$ Million)
Table 70. Europe Human Vaccines Administered Orally Revenue Market Share by Company (2017-2022)
Table 71. Europe Human Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
Table 72. Europe Human Vaccines Administered Orally Sales by Type (2023-2028) & (K Units)
Table 73. Europe Human Vaccines Administered Orally Revenue by Type (2017-2022) & (US$ Million)
Table 74. Europe Human Vaccines Administered Orally Revenue by Type (2023-2028) & (US$ Million)
Table 75. Europe Human Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
Table 76. Europe Human Vaccines Administered Orally Sales by Application (2023-2028) & (K Units)
Table 77. Europe Human Vaccines Administered Orally Revenue by Application (2017-2022) & (US$ Million)
Table 78. Europe Human Vaccines Administered Orally Revenue by Application (2023-2028) & (US$ Million)
Table 79. Europe Human Vaccines Administered Orally Sales by Country (2017-2022) & (K Units)
Table 80. Europe Human Vaccines Administered Orally Sales by Country (2023-2028) & (K Units)
Table 81. Europe Human Vaccines Administered Orally Revenue by Country (2017-2022) & (US$ Million)
Table 82. Europe Human Vaccines Administered Orally Revenue by Country (2023-2028) & (US$ Million)
Table 83. Asia Pacific Human Vaccines Administered Orally Sales by Company (2017-2022) & (K Units)
Table 84. Asia Pacific Human Vaccines Administered Orally Sales Market Share by Company (2017-2022)
Table 85. Asia Pacific Human Vaccines Administered Orally Revenue by Company (2017-2022) & (US$ Million)
Table 86. Asia Pacific Human Vaccines Administered Orally Revenue Market Share by Company (2017-2022)
Table 87. Asia Pacific Human Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
Table 88. Asia Pacific Human Vaccines Administered Orally Sales by Type (2023-2028) & (K Units)
Table 89. Asia Pacific Human Vaccines Administered Orally Revenue by Type (2017-2022) & (US$ Million)
Table 90. Asia Pacific Human Vaccines Administered Orally Revenue by Type (2023-2028) & (US$ Million)
Table 91. Asia Pacific Human Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
Table 92. Asia Pacific Human Vaccines Administered Orally Sales by Application (2023-2028) & (K Units)
Table 93. Asia Pacific Human Vaccines Administered Orally Revenue by Application (2017-2022) & (US$ Million)
Table 94. Asia Pacific Human Vaccines Administered Orally Revenue by Application (2023-2028) & (US$ Million)
Table 95. Asia Pacific Human Vaccines Administered Orally Sales by Region (2017-2022) & (K Units)
Table 96. Asia Pacific Human Vaccines Administered Orally Sales by Region (2023-2028) & (K Units)
Table 97. Asia Pacific Human Vaccines Administered Orally Revenue by Region (2017-2022) & (US$ Million)
Table 98. Asia Pacific Human Vaccines Administered Orally Revenue by Region (2023-2028) & (US$ Million)
Table 99. Latin America Human Vaccines Administered Orally Sales by Company (2017-2022) & (K Units)
Table 100. Latin America Human Vaccines Administered Orally Sales Market Share by Company (2017-2022)
Table 101. Latin America Human Vaccines Administered Orally Revenue by Company (2017-2022) & (US$ Million)
Table 102. Latin America Human Vaccines Administered Orally Revenue Market Share by Company (2017-2022)
Table 103. Latin America Human Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
Table 104. Latin America Human Vaccines Administered Orally Sales by Type (2023-2028) & (K Units)
Table 105. Latin America Human Vaccines Administered Orally Revenue by Type (2017-2022) & (US$ Million)
Table 106. Latin America Human Vaccines Administered Orally Revenue by Type (2023-2028) & (US$ Million)
Table 107. Latin America Human Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
Table 108. Latin America Human Vaccines Administered Orally Sales by Application (2023-2028) & (K Units)
Table 109. Latin America Human Vaccines Administered Orally Revenue by Application (2017-2022) & (US$ Million)
Table 110. Latin America Human Vaccines Administered Orally Revenue by Application (2023-2028) & (US$ Million)
Table 111. Latin America Human Vaccines Administered Orally Sales by Country (2017-2022) & (K Units)
Table 112. Latin America Human Vaccines Administered Orally Sales by Country (2023-2028) & (K Units)
Table 113. Latin America Human Vaccines Administered Orally Revenue by Country (2017-2022) & (US$ Million)
Table 114. Latin America Human Vaccines Administered Orally Revenue by Country (2023-2028) & (US$ Million)
Table 115. Middle East and Africa Human Vaccines Administered Orally Sales by Company (2017-2022) & (K Units)
Table 116. Middle East and Africa Human Vaccines Administered Orally Sales Market Share by Company (2017-2022)
Table 117. Middle East and Africa Human Vaccines Administered Orally Revenue by Company (2017-2022) & (US$ Million)
Table 118. Middle East and Africa Human Vaccines Administered Orally Revenue Market Share by Company (2017-2022)
Table 119. Middle East and Africa Human Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
Table 120. Middle East and Africa Human Vaccines Administered Orally Sales by Type (2023-2028) & (K Units)
Table 121. Middle East and Africa Human Vaccines Administered Orally Revenue by Type (2017-2022) & (US$ Million)
Table 122. Middle East and Africa Human Vaccines Administered Orally Revenue by Type (2023-2028) & (US$ Million)
Table 123. Middle East and Africa Human Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
Table 124. Middle East and Africa Human Vaccines Administered Orally Sales by Application (2023-2028) & (K Units)
Table 125. Middle East and Africa Human Vaccines Administered Orally Revenue by Application (2017-2022) & (US$ Million)
Table 126. Middle East and Africa Human Vaccines Administered Orally Revenue by Application (2023-2028) & (US$ Million)
Table 127. Middle East and Africa Human Vaccines Administered Orally Sales by Country (2017-2022) & (K Units)
Table 128. Middle East and Africa Human Vaccines Administered Orally Sales by Country (2023-2028) & (K Units)
Table 129. Middle East and Africa Human Vaccines Administered Orally Revenue by Country (2017-2022) & (US$ Million)
Table 130. Middle East and Africa Human Vaccines Administered Orally Revenue by Country (2023-2028) & (US$ Million)
Table 131. Merck Corporation Information
Table 132. Merck Description and Overview
Table 133. Merck Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Table 134. Merck Human Vaccines Administered Orally Product and Services
Table 135. Merck Human Vaccines Administered Orally SWOT Analysis
Table 136. Merck Recent Developments
Table 137. GSK Corporation Information
Table 138. GSK Description and Overview
Table 139. GSK Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Table 140. GSK Human Vaccines Administered Orally Product and Services
Table 141. GSK Human Vaccines Administered Orally SWOT Analysis
Table 142. GSK Recent Developments
Tab
  • Global Genitourinary Partnering 2010-2022: Deal trends, players and financials
    Published: 01-Dec-2022        Price: US 3995 Onwards        Pages: 400
    Global Genitourinary Partnering 2010 to 2022 provides the full collection of genitourinary disease deals signed between the world's pharmaceutical and biotechnology companies since 2010. Trends in genitourinary partnering deals Financial deal terms for headline, upfront and royalty by stage of development Genitourinary partnering agreement structure Genitourinary partnering contract documents Top genitourinary deals by value Most active genitourinary d......
  • Global Noscapine Base Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
    Published: 30-Nov-2022        Price: US 5600 Onwards        Pages: 101
    Report Scope This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers' production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Noscapine Base manufacturers, distributors, end users, industry associations, governments' industry bureaus, industry publi......
  • Global Specialty Generics Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
    Published: 30-Nov-2022        Price: US 5600 Onwards        Pages: 113
    Report Scope This latest report researches the industry structure, revenue and gross margin. Major players' headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Specialty Generics companies, distributors, end users, industry associations, governments' industry bureaus, industry publications, industry expert......
  • Global Generic and Biosimilar Pharmaceuticals Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
    Published: 30-Nov-2022        Price: US 5600 Onwards        Pages: 118
    Report Scope This latest report researches the industry structure, revenue and gross margin. Major players' headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Generic and Biosimilar Pharmaceuticals companies, distributors, end users, industry associations, governments' industry bureaus, industry publicati......
  • Global Secondary Antibody Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
    Published: 30-Nov-2022        Price: US 5600 Onwards        Pages: 111
    Report Scope This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers' production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Secondary Antibody manufacturers, distributors, end users, industry associations, governments' industry bureaus, industry p......
  • Global Primary Antibody Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
    Published: 30-Nov-2022        Price: US 5600 Onwards        Pages: 115
    Report Scope This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers' production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Primary Antibody manufacturers, distributors, end users, industry associations, governments' industry bureaus, industry pub......
  • Global Animal Troponin Antibody Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
    Published: 30-Nov-2022        Price: US 5600 Onwards        Pages: 126
    Report Scope This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers' production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Animal Troponin Antibody manufacturers, distributors, end users, industry associations, governments' industry bureaus, indu......
  • Global Human Troponin Antibody Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
    Published: 30-Nov-2022        Price: US 5600 Onwards        Pages: 127
    Report Scope This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers' production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Human Troponin Antibody manufacturers, distributors, end users, industry associations, governments' industry bureaus, indus......
  • Global Troponin Antibody Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
    Published: 30-Nov-2022        Price: US 5600 Onwards        Pages: 125
    Report Scope This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers' production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Troponin Antibody manufacturers, distributors, end users, industry associations, governments' industry bureaus, industry pu......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs